Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/1556
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorTIBURCIO, Marta-
dc.contributor.authorCOSTA, Sandra M. A.-
dc.contributor.authorDUARTE, Maria De Fatima-
dc.contributor.authorSCHMITT, Fernando C.-
dc.contributor.authorLONGATTO FILHO, Adhemar-
dc.date.accessioned2013-07-30T17:53:34Z-
dc.date.available2013-07-30T17:53:34Z-
dc.date.issued2012-
dc.identifier.citationONCOLOGY LETTERS, v.4, n.4, p.647-657, 2012-
dc.identifier.issn1792-1074-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/1556-
dc.description.abstractBreast cancer is the most common cause of cancer mortality among women worldwide. Among the several factors associated with breast cancer development, angiogenesis plays an essential role and has currently emerged as a potential diagnostic, prognostic and therapeutic target. Protease-activated receptor 1 (PAR1) and fibroblast growth factor receptor 1 (FGFR1) have important activities in tumor angiogenesis and progression. The aim of this study was to investigate the prognostic significance of these two receptors, hypothesising significant correlations between receptor expression in tumor angiogenesis and clinicopathological parameters customarily used in breast cancer prognosis and prediction. Formalin-fixed and paraffin-embedded samples of ductal invasive breast carcinomas were used to analyze the expression of PAR1 and FGFR1, in the tumor cells as well as in the tumor stroma, and further determine intratumoral microvessel density (iMVD) to quantify intratumoral angiogenesis. Correlations between PAR1 and FGFR1 expression in tumor cells and stroma, iMVD and several clinicopathological parameters and molecular markers used in breast cancer diagnosis have been addressed. The correlation between PAR1 and FGFR1 suggests an association of the two receptors with a more aggressive breast cancer phenotype and, consequently, a potential role during tumor progression. The results reported in the present study also emphasize the importance of microenvironmental factors in tumor progression, while precluding the positive association between iMVD and breast cancer aggressiveness.-
dc.description.sponsorship[Pest-C/CTM/LA0011/2011]-
dc.language.isoeng-
dc.publisherSPANDIDOS PUBL LTD-
dc.relation.ispartofOncology Letters-
dc.rightsopenAccess-
dc.subjectprotease-activated receptor 1-
dc.subjectfibroblast growth factor receptor 1-
dc.subjectinvasive breast cancer-
dc.subject.othersmooth-muscle-cells-
dc.subject.othercancer cells-
dc.subject.otherp-cadherin-
dc.subject.otherin-situ-
dc.subject.otherreceptor-
dc.subject.otherangiogenesis-
dc.subject.otheractivation-
dc.subject.othersurvival-
dc.subject.othermammary-
dc.subject.othertransactivation-
dc.titleCharacterization of PAR1 and FGFR1 expression in invasive breast carcinomas: Prognostic significance-
dc.typearticle-
dc.rights.holderCopyright SPANDIDOS PUBL LTD-
dc.identifier.doi10.3892/ol.2012.806-
dc.identifier.pmid23205078-
dc.subject.wosOncology-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-
hcfmusp.author.externalTIBURCIO, Marta:Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, Braga, Portugal; PT Govt Associate Lab, ICVS 3Bs, Braga, Portugal-
hcfmusp.author.externalCOSTA, Sandra M. A.:Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, Braga, Portugal; PT Govt Associate Lab, ICVS 3Bs, Braga, Portugal-
hcfmusp.author.externalDUARTE, Maria De Fatima:Univ Aveiro, Ctr Res Ceram & Composite Mat CICECO, P-3800 Aveiro, Portugal-
hcfmusp.author.externalSCHMITT, Fernando C.:Univ Porto, Fac Med, Dept Pathol, P-4100 Oporto, Portugal; Univ Porto, IPATIMUP Inst Mol Pathol & Immunol, P-4100 Oporto, Portugal-
hcfmusp.description.beginpage647-
hcfmusp.description.endpage657-
hcfmusp.description.issue4-
hcfmusp.description.volume4-
hcfmusp.origemWOS-
hcfmusp.origem.id2-s2.0-84864690484-
hcfmusp.origem.idWOS:000308839900013-
hcfmusp.publisher.cityATHENS-
hcfmusp.publisher.countryGREECE-
hcfmusp.relation.referenceAgarwal A, 2008, MOL CANCER THER, V7, P2746, DOI 10.1158/1535-7163.MCT-08-0177-
hcfmusp.relation.referenceBassus S, 2001, ARTERIOSCL THROM VAS, V21, P1550, DOI 10.1161/hq0901.095148-
hcfmusp.relation.referenceBoire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018-
hcfmusp.relation.referenceBourdon JC, 2007, BRIT J CANCER, V97, P277, DOI 10.1038/sj.bjc.6603886-
hcfmusp.relation.referenceBrenton JD, 2005, J CLIN ONCOL, V23, P7350, DOI 10.1200/JCO.2005.03.3845-
hcfmusp.relation.referenceD'Andrea MR, 2001, AM J PATHOL, V158, P2031, DOI 10.1016/S0002-9440(10)64675-5-
hcfmusp.relation.referenceDelafontaine P, 1996, J CLIN INVEST, V97, P139, DOI 10.1172/JCI118381-
hcfmusp.relation.referenceDuarte M, 2006, BIOCHEM BIOPH RES CO, V350, P604, DOI 10.1016/j.bbrc.2006.09.107-
hcfmusp.relation.referenceElsheikh SE, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1665-
hcfmusp.relation.referenceEven-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909-
hcfmusp.relation.referenceFerlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516-
hcfmusp.relation.referenceGrose R, 2005, CYTOKINE GROWTH F R, V16, P179, DOI 10.1016/j.cytogfr.2005.01.003-
hcfmusp.relation.referenceHanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013-
hcfmusp.relation.referenceHasan J, 2002, BRIT J CANCER, V86, P1566, DOI 10.1038/sj/bjc/6600315-
hcfmusp.relation.referenceHernandez NA, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-47-
hcfmusp.relation.referenceLopes N, 2009, HISTOPATHOLOGY, V55, P594, DOI 10.1111/j.1365-2559.2009.03417.x-
hcfmusp.relation.referenceMarinho A, 1997, PATHOL RES PRACT, V193, P267-
hcfmusp.relation.referenceO'Brien PJ, 2000, J BIOL CHEM, V275, P13502, DOI 10.1074/jbc.275.18.13502-
hcfmusp.relation.referenceParedes J, 2008, J CLIN PATHOL, V61, P856, DOI 10.1136/jcp.2007.052704-
hcfmusp.relation.referenceParedes J, 2002, VIRCHOWS ARCH, V440, P16, DOI 10.1007/s004280100487-
hcfmusp.relation.referencePusztai L, 2008, ONCOLOGIST, V13, P350, DOI 10.1634/theoncologist.2007-0216-
hcfmusp.relation.referenceRauch BH, 2004, CIRC RES, V94, P340, DOI 10.1161/01.RES.0000111805.09592.D8-
hcfmusp.relation.referenceReis JS, 2006, CLIN CANCER RES, V12, P6652, DOI 10.1158/1078-0432.CCR-06-1164-
hcfmusp.relation.referenceSchwertfeger KL, 2009, CURR DRUG TARGETS, V10, P632-
hcfmusp.relation.referenceSuyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2-
hcfmusp.relation.referenceVU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V-
hcfmusp.relation.referenceWeigelt B, 2008, J PATHOL, V216, P141, DOI 10.1002/path.2407-
hcfmusp.relation.referenceWeigelt B, 2009, NAT REV CLIN ONCOL, V6, P718, DOI 10.1038/nrclinonc.2009.166-
hcfmusp.relation.referenceWelm BE, 2002, J CELL BIOL, V157, P703, DOI 10.1083/jcb.200107119-
hcfmusp.relation.referenceWinter SF, 2007, ONCOGENE, V26, P4897, DOI 10.1038/sj.onc.1210288-
hcfmusp.relation.referenceXian W, 2005, J CELL BIOL, V171, P663, DOI 10.1083/jcb.200505098-
hcfmusp.relation.referenceYang E, 2009, CANCER RES, V69, P6223, DOI 10.1158/0008-5472.CAN-09-0187-
hcfmusp.relation.referenceYin YJ, 2003, FASEB J, V17, P163, DOI 10.1096/fj.02-0316com-
dc.description.indexPubMed-
hcfmusp.lim.ref2012-
hcfmusp.citation.scopus7-
hcfmusp.scopus.lastupdate2022-07-08-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - LIM/14
LIM/14 - Laboratório de Investigação em Patologia Hepática


Files in This Item:
File Description SizeFormat 
art_LONGATTO FILHO_Characterization_of_PAR1_and_FGFR1_expression_in_invasive_2012.PDFpublishedVersion (English)917.47 kBAdobe PDFThumbnail
View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.